Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is pz-cel, an autologous, engineered cell therapy that is in a Phase 1/2a clinical trialfor recessive dystrophic epidermolysis bullosa.
The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
| Country | United States |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Vishwas Seshadri |
Contact Details
Address: 6555 Carnegie Avenue, 4th Floor Cleveland, Ohio 44103 United States | |
| Phone | 646 813 4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Joseph Walter Vazzano C.P.A. | Chief Financial Officer |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer |
| Brian Kevany Ph.D. | Senior Vice President, Chief Technology Officer and CSO |
| Gregory Gin | Vice President of Investor Relations and Corporate Communications |
| Alison Hardgrove | Chief People Officer |
| Jon Voss | Vice President and Head of Quality |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior Vice President, Chief Commercial Officer and Head of Business Development |
| Carl Denny | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | 144 | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Jan 29, 2025 | 144 | Filing |
| Jan 21, 2025 | 144 | Filing |
| Jan 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |